Bordetella pertussis attachment to respiratory epithelial cells can be impaired by fimbriae-specific antibodies by Rodríguez, María Eugenia et al.
Bordetella pertussis attachmentto respiratory epithelial cells can 
be impaired by f imbriae-specif ic antibodies
Maria Eugenia Rodríguez1,2, Sandra M.M. Hellwig2,4*, María L.A. Pérez Vidakovics1, GuyA.M. Berbers4 
& Jan G. J. van de Winkel2,3
1CINDEFI, Faculty of Science, La Plata University, La Plata, Argentina; immunotherapy Laboratory, Department of Immunology; 3Genmab, University 
Medical Center, Utrecht, The Netherlands; and laboratory for Vaccine Preventable Diseases, National Institute of Public Health and the Environment, 
Bilthoven, The Netherlands
Correspondence: Maria Eugenia Rodríguez, 
CINDEFI, Facultad de Ciencias Exactas, 
Universidad Nacional de la Plata, calles 47 y 
11 5, 1900 La Plata, Argentina. Tel./fax: 
+ 54 221 4833794; e-mail: 
mer@quimica.unlp.edu.ar
* Present address: Genmab, University 
Medical Center, Utrecht, The Netherlands.
Received 25 February 2005; revised 7 June 
2005; accepted 20 June 2005.
First published online 7 September 2005.
do i: 10.1111/j. 1574-695X.2005.00001 .x
Abstract
Bordetella pertussis attachment to host cells is a crucial step in colonization. In this 
study, we investigated the specificity of antibodies, induced either by vaccination 
or infection, capable of reducing bacterial adherence to respiratory epithelial cells. 
Both sera and purified anti-B. pertussis IgG or IgA fractions efficiently reduced 
attachment. This effect was found to be mediated mainly by fimbriae-specific 
antibodies. Antibodies with other specificities did not significantly interfere in the 
interaction of B. pertussis with respiratory epithelial cells, with the exception of 
antifilamentous hemaglutinin antibodies, which reduced bacterial attachment. 
However, this effect was smaller in magnitude than that observed in the presence of 
fimbriae-specific antibodies. The strong agglutinating activity of antifimbriae 
antibodies seems to be involved in this phenomenon.
Editor: Jennelle Kyd
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Introduction
Bordetella pertussis is the etiologic agent of whooping cough, 
a disease that is re-emerging in many parts of the world 
despite high vaccination coverage. The side effects of whole­
cell pertussis vaccines have prompted the development of 
acellular vaccines containing purified B. pertussis virulence 
factors. However, the combination of antigens inducing 
optimal efficacy is still unclear. Detailed insight into me­
chanisms protective against B. pertussis should facilitate a 
more rational selection of vaccine components.
Bordetella pertussis is an obligate human pathogen infecting 
the respiratory tract. The interaction between B. pertussis and 
the host involves several virulence factors. Surface-associated 
proteins such as fimbriae (Fim), filamentous hemaglutinin 
(FHA) and pertactin (Prn), have all been implicated in 
bacterial attachment to host cells, whereas toxins such as 
pertussis toxin (Ptx), adenylate cyclase toxin (Cya), lipopoly­
saccharide (LPS), among others, are regarded as being respon­
sible for pertussis symptoms (Hewlett, 1997; Locht, 1999).
The relative contribution of humoral and cellular immu­
nity on host protection against B. pertussis is still under 
investigation. However, efficient bacterial elimination from 
the respiratory tract might require both. Antibodies against 
several virulence factors were found to be correlated with 
clinical protection in humans (Cherry et al., 1998; Storsaeter 
et al., 1998). Antibodies may provide protection in several 
ways. They may neutralize toxins, interfere with attachment 
to respiratory cells, or facilitate bactericidal activity by 
immune cells. We have previously documented that B. 
pertussis-specific antibodies are required for the induction 
of cellular bactericidal effector functions (Rodríguez et al., 
2001a), and that Prn-specific antibodies play a key role in 
promoting B. pertussis uptake by professional phagocytes 
(Hellwig et al., 2003). The specificity of antibodies capable 
of preventing attachment, however, remains unclear. Studies 
have shown the existence of antiadherence activity in sera 
from individuals either vaccinated or infected by B. pertussis 
(Tuomanen et al., 1984). The authors detected this activity 
both in IgG and IgA antibody classes, but they did not 
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investigate the specificity of the antibodies involved. Both 
anti-FHA and anti-PT mouse antibodies have been shown to 
be capable of decreasing B. pertussis attachment to mouse 
fibroblasts (Lenin et al., 1986). Later studies demonstrated 
that mouse antibodies with other specificities are able to 
reduce B. pertussis attachment to bronchial epithelial cells 
(van den Berg et al., 1999).
The present study was performed to investigate further 
the specificity of antibodies, induced by vaccination or 
infection, that efficiently prevent bacterial interaction with 
the respiratory epithelia.
Material and methods
Bacterial strains and growth conditions
The virulent B. pertussis strain B213, a streptomycin-resis­
tant derivative of Tohama, BpGR4, a Tohama-derived mu­
tant lacking expression of FHA (Locht et al., 1992), and 
strain B316, a Tohama-derived mutant lacking expression of 
Fim2, Fim3 and FimD (Geuijen et al., 1996), were used in 
this study.
Bacteria were stored at — 70 C and recovered by growth 
on Bordet-Gengou (BG) agar plates at 35 C for 3 days. 
Virulent bacteria were subsequently plated on BG plates, 
cultured overnight, and used in the experiments.
Sera and antibodies
Sera from 24 Dutch children enrolled in a clinical trial to 
study efficacy of pertussis vaccines (Berbers et al., 1999) 
were used in this study (Table 1). Written informed consent 
was obtained from a parent, guardian or adult before 
enrollment. This study was approved by the institutional 
review board of the National Institute of Public Health 
and the Environment, The Netherlands. Children were 
vaccinated with Dutch whole-cell vaccine in the first year of 
life and boostered with: (1) an acellular pertussis vaccine 
Table 1. Specific antibody titers and agglutinating activity of serum samples from donors after pertussis booster vaccination (serum 1-24), and IgG and 
IgA fractions of pooled sera from pertussis-infected donors
Donor
Virulence factors*-*
Agglutinating 
activity
Attachment level*-® 
(bacteria per cell)PTx FHA Prn Firn
1 16 607 828 96 32 150
2 68 222 349 64 32 120
3 170 1332 599 175 64 180
4 1065 2232 454 457 256 74
5 148 981 305 76 32 159
6 30 199 33 12 4 241
7 1411 430 156 212 256 92
8 24 48 518 45 16 193
9 81 66 26 43 32 233
10 109 2148 156 136 128 112
11 83 138 120 69 8 192
12 69 1293 154 23 4 243
13 342 279 339 157 8 202
14 8 107 78 57 4 223
15 496 109 517 158 64 120
16 98 232 56 94 64 138
17 1 45 56 1478 512 5
18 6 33 115 152 128 105
19 52 100 104 344 256 61
20 6 31 7 174 256 72
21 105 79 44 416 256 52
22 25 28 32 149 128 120
23 36 24 25 855 1280 53
24 3 109 333 281 512 51
IgG 4354 1247 822 2487 800 8
IgA 93 310 73 954 400 18
* Antibody titers are expressed in ELISA units per mL calculated relative to the US reference pertussis antiserum.
Treimmune sera showed no detectable antibody titers against Bordetella pertussis.
*By means of four independent determinations.
§No significant differences of bacterial attachment levels were detected in the presence or the absence of the different preimmune sera. 
Ptx, pertussis toxin; FHA, filamentous hemaglutinin; Prn, pertactin.
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consisting of Ptx, FHA and Prn (GSK Rixensart Belgium, 
donors 1-14); (2) an acellular pertussis vaccine consisting of 
Ptx, FHA, Prn and Fim (Wyeth Lederle/Takeda, donors 15 
and 16) or (3) Dutch whole-cell vaccine (donors 17-24) at 4 
years of age. Sera samples were taken before and after 
vaccination. IgG and IgA fractions from pooled sera of 
pertussis-infected individuals were purified as described 
(van der Pol et al., 2000). Depletion of either anti-Fim or 
anti-Prn antibodies from sera, and IgG- or IgA-containing 
fractions was performed as in Hellwig et al. (2003). The 
purity of both Fim2,3 and Prn antigens used for depletion 
was confirmed by sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE) and immunoblot analyses. 
Incubation of sera with the different proteins (Fim2,3 or 
Prn), selectively depleted antibodies specific for the respec­
tive antigen. The titers of antibodies with the other specifi­
cities (namely, FHA, PTx, and either Prn or Fim) remained 
unchanged, as assessed by enzyme linked immunosorbent 
assay (ELISA) before and after depletion. In order to rule 
out a possible role of the presence of purified Prn or Fim on 
bacterial adherence, both proteins were tested for their 
ability to influence bacterial attachment in the concentra­
tions used for depletion. No effect on bacterial adherence to 
epithelial cells could be detected in the presence of any of 
these proteins (data not shown).
Rabbit anti-Fim serum was obtained as follows. Patho­
gen-free rabbits were immunized with 500 pg of purified 
Fim2,3 (Netherlands Vaccine Institute, Bilthoven, The Neth­
erlands). Further immunizations were performed at 3 and 6 
weeks. Sera were collected 7 weeks after primary immuni­
zation.
The following monoclonal antibodies (mAbs) against B. 
pertussis antigens were used: 118E10 (IgGl) against B. 
pertussis Fim, 13E11 (IgM) against B. pertussis Prn, 4-37F3 
(IgGl) against B. pertussis FHA (Poolman et al., 1990) (all 
kindly provided by the Netherlands Vaccine Institute, Na­
tional Institute of Public Health and the Environment, The 
Netherlands).
Cells and growth conditions
The human alveolar epithelial cell line A549 (ATCC 
CCL185) (Rockville, MD, USA) was grown in RPMI 1640 
medium (Gibco, USA), supplemented with 10% heat-in- 
activated fetal calf serum (FCS), 100 U mL ~ 1 penicillin, and 
100 pg mL 1 streptomycin (Sigma, St Louis, MO, USA) 
(complete medium) at 37 C in 5% CO2.
ELISA and bacterial agglutination
Antibody titers against Ptx, FHA, Prn, and Fim2 were 
determined by ELISA as described previously (Meade et al., 
1995). Briefly, 96-well plates were coated with purified Ptx, 
FHA, Fim2 (all from the Netherlands Vaccine Institute), or 
Prn (from Chiron, Siena, Italy) at concentrations of 1, 2, 
and 3pgmL \ respectively. For each serum, a series of 
eight two-fold dilutions was tested, starting with a 1:60 
dilution. Bound IgG was detected after 2 h incubation 
(room temperature) with alkaline phosphatase-conjugated 
goat antihuman IgG (Sigma) (working dilution: 30 000). 
ELISA units (EU) were calculated relative to the US Refer­
ence Pertussis Antiserum (human, obtained from the FDA), 
lot 3 for Ptx, FHA and Fim, and lot 4 for Prn using the four 
parameter fit method in KC4 (Kineticalc for Windows), with 
a BioTek plate reader (EL312e, BioTek, Winooski, VT, USA). 
The minimum level of detection was estimated at 2 
EUml. 1 for anti-Ptx and anti-FHA antibodies, 4 EUml. 
for anti-Prn antibodies, and 2 EU mL ~1 for anti-Fim2 
antibodies.
Agglutinating antibodies were measured essentially as 
described by Nagel et al. (1985) using B. pertussis strain 
3838 as antigen. US Pertussis antiserum was used as a 
reference and a control serum was included on each plate. 
For each serum, a two-fold dilution series in eight wells was 
tested (starting with a 1 :4 dilution). The agglutination titer 
is expressed as the reciprocal of the highest final dilution of 
serum inducing agglutination.
Attachment assays
Attachment assays were performed as described previously 
(Sisti et al., 2002) with minor modifications. Briefly, A549 
cells were grown in complete medium using 24-well tissue 
culture plates (Nunc, Roskilde, Denmark) for 18 h. Mono- 
layers were washed twice with RPMI 1640 medium supple­
mented with 10% FCS prior to incubation with virulent B. 
pertussis (500 bacteria per cell) in the absence or presence of 
sera (0-10% v/v), purified IgG (0-100 pg mL 1), purified 
IgA (0-100 pg mL x), or mAbs (0-30 pg mL J). Bacterial 
inocula were quantified using appropriate dilutions onto BG 
plates. To facilitate bacterial interaction with epithelial cells, 
plates were centrifuged for 5 min at 640 g. Adherence of 
bacteria to A549 cells was determined after 2 h of incubation 
at 37 °C (with 5% CO2). No changes in the number of viable 
A549 cells were detected upon infection. Experiments were 
stopped by washing the monolayers with RPMI 1640 
medium supplemented with 10% FCS, prior to fixation 
with methanol. Bacterial adherence was quantified by mi­
croscopy after crystal violet staining. Adherent bacteria were 
counted by microscopic examination of 20 randomly- 
selected fields, showing a minimum of seven epithelial cells 
per field.
Phagocytosis
Phagocytosis of opsonized B. pertussis was performed as 
described in Rodríguez et al. (2001a, b) with minor 
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modifications. Briefly, GFP-labeled B. pertussis were incu­
bated with 10% (v/v) serum, IgG (300 pig ml. x), or IgA 
(300 pig ml. x), for 30 min at 37 °C. Opsonized bacteria 
were allowed to attach to freshly isolated human polymor­
phonuclear leucocyte cells in a ratio of 70 :1 for 30 min 
at 4 After extensive washing to remove nonattached 
bacteria, cells were split into two aliquots, and further 
incubated for 30 min at either 4 or 37 °C. Subsequently, 
remaining cell surface-bound opsonized bacteria were de­
tected by incubation for 30 min at 4 °C with phycoerythrin 
(PE)-conjugated goat F(ab')2 fragments of antihuman IgG, 
or PE-conjugated goat F(ab')2 fragments of antihuman IgA 
(Southern Biotechnology, Birmingham, AL, USA). After 
washing, samples were analyzed using flow cytometry. Five 
thousand cells were analyzed per sample. Green and red 
fluorescence intensities of cells maintained at 4 C served as 
control for bacterial binding (i.e. 0% phagocytosis). The 
decrease in red fluorescence of green cells after incubation at 
37 C reflected bacterial phagocytosis, and were used to 
calculate phagocytosis as described previously (Rodriguez 
etal., 2001b).
Statistical analyses
Antibody titers were converted to log 10 values before 
analyses for linear correlation. Pearson’s product moment 
correlation coefficient was calculated for the inverse of log- 
converted antibody titers against selected bacterial antigens 
and bacterial attachment levels. Student’s t-les Is were used 
to assess the significance of differences between averages. 
Significance was accepted at P < 0.05.
Results
The A549 cell line has previously been used to investigate the 
involvement of B. pertussis virulence factors on bacterial 
interaction with human respiratory epithelial cells (Schipper 
etal., 1994; Alonso et al., 2001; Ishibashi etal., 2001; Coutte 
et al., 2003). We employed this model system to study the 
capacity of specific antibodies to prevent B. pertussis attach­
ment to respiratory cells. As reported before by Tuomanen 
et al. (1984), using human ciliated tracheal cells to study B. 
pertussis attachment, we observed that the addition of sera 
from pertussis-vaccinated individuals with detectable titers 
of specific antibodies decreased bacterial adherence to A549 
cells (Table 1). Regression analyses (n = 24) suggested that 
this decrease was mainly due to the presence of antibodies 
directed against Fim (r=0.84, P < 0.05). The level of 
antibodies against Prn, Ptx, or FHA showed no correlation 
with bacterial attachment decrease (r= —0.125, P < 0.05; 
r= — 0.058, P < 0.05 and r = — 0.30, P < 0.05, respectively). 
Serum samples obtained prior to booster vaccination, 
without detectable antibody titers against B. pertussis, did 
not influence bacterial attachment to respiratory epithelial 
cells (Fig. la).
To investigate the importance of Fim-specific antibodies, 
further sera with different levels of anti-Fim antibodies 
(serum 2 and serum 4, Table 1) were depleted of antibodies 
aganist Fim or Prn (the latter used as a control). As observed 
before (Hellwig et al., 2003), antibodies directed against the 
other B. pertussis antigens tested (namely, FHA, Ptx, and 
Prn) remained unaffected by this procedure as checked by 
ELISA (data not shown). In agreement with the regression 
analyses, depletion of anti-Fim antibodies abrogated almost 
completely the inhibitory effect of anti-B. pertussis antibo­
dies on bacterial attachment, whereas depletion of Prn 
antibodies did not have an effect (Fig. la).
Similar results were obtained with B. pertussis IgA and 
IgG purified from sera of pertussis patients with high titers 
against B. pertussis. Both isotypes proved to be capable of 
interfering with bacterial attachment (Table 1) and Fim- 
directed antibodies were shown to play the main role. 
Depletion of anti-Fim, but not anti-Prn IgG or IgA, abro­
gated the inhibition of bacterial attachment (Fig. la).
This activity of anti-Fim antibodies was further con­
firmed using two different sources of antibodies, a rabbit 
anti-Fim serum and anti-Fim monoclonal antibodies 
(mAbs). Both anti-Fim rabbit antiserum and mAbs effi­
ciently reduced bacterial attachment (Fig. lb), whereas anti- 
Prn mAb did not (Fig. lb). Figure lc shows that bacterial 
attachment inhibition with anti-Fim antibodies is dose­
dependent, whereas no influence of anti-Prn antibodies on 
bacterial adherence was detected using equivalent concen­
trations. Similar results were obtained using Fim and Prn 
antisera (data not shown).
Importantly, FHA but not Fim has been described 
previously as the main adhesin of B. pertussis. However, 
antibodies against FHA proved to be capable of reducing 
bacterial attachment less efficiently (P < 0.05) than anti- 
Fim antibodies (Fig. Id). We investigated therefore the 
relative importance of these two adhesins on B. pertussis 
attachment to the human cells used in our study (A549). 
Using B. pertussis mutants lacking expression of either FHA 
(BpGR4) or both the major and the minor Fim subunits 
(Bp316), we found FHA but not Fim to be crucial for B. 
pertussis attachment to A549 cells (Fig. Id).
Together, these results suggest that anti-Fim antibodies do 
not primarily block adhesive epitopes on the fimbrial 
protein, but they interfere with bacterial attachment by a 
different Fim-dependent mechanism. In agreement with 
this hypothesis, we found that, although the B. pertussis 
isogenic mutant lacking expression of Fim proved to adhere 
to epithelial cells in a similar way as did wild-type bacteria, 
the attachment of Fim-mutant isogenic strain was not 
inhibited by immune sera that efficiently decreased the 
wild-type B. pertussis (B213) attachment level (Fig Id).
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Antibody concentration (pg mL
Fig. 1. Effect of specific antibodies on Bordetella pertussis attachment to human respiratory epithelial cells, A549. (a) B. pertussis was added to A549 
cell monolayers in the presence or absence of serum, purified IgG, and IgA isotypes (10% v/v, 100 and 100 pg mL "respectively) before (serum, IgG, 
IgA), and after depletion of either Fim-directed antibodies (serum anti-Fim depleted, IgG anti-Fim depleted, IgA anti-Fim depleted) or Prn directed 
antibodies (serum anti-Prn depleted, IgG anti-Prn depleted, IgA anti-Prn depleted). Bacterial attachment to epithelial cells in the absence of antibodies 
(control) or in the presence of serum with no detectable antibodies to B. pertussis (nonimmune serum, 10% v/v) was determined in every assay. Data 
represent mean ± SD of four independent experiments, (b) Anti-Fim and anti-Prn monoclonal antibodies (30 pg mL 1), and rabbit anti-Fim antibodies 
(30 pg mL ’) were tested for their ability to reduce B. pertussis attachment to epithelial cells. Nonimmune serum was included in every experiment as a 
control. Data represent mean ± SD of four independent experiments, (c) Effect of anti-Fim (□), and anti-Prn (A) monoclonal antibody concentrations 
on B. pertussis attachment to A549 cells. The different concentrations were tested in three independent experiments. The decrease of bacterial 
attachment level proved significant in the presence of 5, 10, 20 and 30 pg mL 1 anti-Fim antibodies. Data represent mean ± SD. (d) Relevance of Fim 
and FHA as adhesins and/or targets for antibody-dependent B. pertussis attachment inhibition. Attachment of B. pertussis (B213), B. pertussis 
Fim deficient mutant (B316), and B. pertussis FHA deficient mutant (BpGR4) to epithelial cells in the presence and absence of immune serum (serum 4, 
10% v/v) was determined. Attachment of B. pertussis (B213) to respiratory cells was further evaluated in the presenceof either anti-Fim (30 pg mL ’) or 
anti-FHA (30 pg mL ’) antibodies. Data represent mean ± SD of four independent experiments.
Anti-Fim antibodies have previously been described as 
agglutinins (Li et al., 1988a). Bacterial agglutination may 
preclude attachment. Similarly, we found sera agglutinating 
activity highly correlated with both anti-Fim antibody titers 
(r = 0.81, P < 0.05) and the decrease in attachment levels of 
wild-type bacteria (r = 0.82, P < 0.05). Microscopic evalua­
tion of B. pertussis incubated with either immune sera 
(containing high titers of anti-Fim antibodies) or rabbit
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Fig. 2. Anti-Fim antibodies and Bordetella per­
tussis attachment to A549 cells, (a) B. pertussis 
were incubated for 2 h with A549 cells in the 
absence (1), or presence of immune serum (2), 
immune serum depleted of anti-Fim antibodies 
(3), or rabbit B. pertussis anti-Fim antibodies (4). 
Bacteria can be observed in association with 
A549 cells (solid arrows), (b) Agglutinating 
activity of anti-Fim antibodies. Bordetella 
pertussis were incubated for 30 min at 37 °C 
with (1) medium alone, RPMI 1640 medium 
supplemented with 10% FCS, (2) immune 
serum, (3) immune serum depleted of anti-Fim 
antibodies, or (4) rabbit B. pertussis anti-Fim 
antibodies. Panels are representative of one out 
of five independent experiments.
anti-Fim serum, showed wild-type bacteria highly aggluti­
nated, but not the Fim-deficient mutant. Figure 2 shows that 
serum depletion of Fim-directed antibodies determined the 
loss of agglutinating activity and an increase in the number 
of attached bacteria per cell to a level close to that achieved 
in the absence of serum. Additionally, although neither Fim- 
nor Prn-directed monoclonal antibodies agglutinated bac­
teria when tested at lpgmL \ monoclonal antibodies 
directed against Fim, but not against Prn, proved capable of 
agglutinating wild type bacteria when tested at 5, 10, 20 and 
30 pg mL 1 (data not shown). These were concentrations at 
which bacterial attachment was found to be drastically 
decreased (see Fig. lc).
Antibody-mediated phagocytosis plays a central role in 
the induction of bactericidal cellular effector functions 
(Rodríguez et al., 2001a). Agglutination of bacteria may 
facilitate bacterial uptake by professional phagocytes. We 
assessed therefore the opsonic activity of sera that showed 
high agglutinating activity before and after anti-Fim anti­
body depletion. The lack of agglutinating activity after anti- 
Fim antibody depletion was checked by microscopy. Sera 
from children that had been vaccinated, and purified IgG 
and IgA from infected individuals, induced efficient phago­
cytosis of B. pertussis (Fig. 3a). However, Fim-specific 
antibodies and bacterial agglutination were not found to be 
relevant for bacterial uptake by neutrophils (Fig. 3b).
Discussion
Bordetella pertussis is an obligate human pathogen that 
resides in the respiratory tract during infection. Bacterial 
interaction with human respiratory epithelial cells theoreti­
cally constitutes a key event in host colonization and 
whooping cough pathogenesis. Host cell surface receptors 
and several bacterial factors are thought to be involved in 
adhesion of B. pertussis, and a number of adhesins have been 
identified (Leininger et al., 1992; Kerr & Matthews, 2000). 
Despite a large number of studies dealing with bacterial 
factors involved in this process, there are few data on the 
capacity of specific antibodies to prevent B. pertussis attach­
ment to host cells. Previous work has shown that the 
presence of immune sera decreases B. pertussis attachment 
to human ciliated cells. This antiadherence activity was 
reported for both IgG and IgA fractions (Tuomanen et al., 
1984), yet the specificity of the antibodies involved was not 
identified. Consistent with these results, we found sera from 
pertussis-vaccinated individuals that efficiently decreased 
B. pertussis attachment to respiratory cells. Preimmune sera,
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Fig. 3. Effect of Fim-directed antibodies on Bordetella pertussis phago­
cytosis by human PMN. (a) Serum, IgG and IgA isotypes were tested in 
their ability to induce phagocytosis of B. pertussis. Opsonized GFP- 
expressing B. pertussis were incubated with PMN at 4 °C for 30 min. 
Suspensions were then split in two aliquots, and subsequently incubated 
for 30 min at either 4 or 37 °C. Remaining surface-bound IgG-opsonized 
B. pertussis were detected by addition of PE-conjugated goat F(ab')2 
fragments of antihuman IgG antibodies, (b) PMN phagocytosis of B. 
pertussis opsonized with serum, IgG, and IgA before (serum, IgG, IgA), 
and after anti-Fim antibody depletion (serum anti-Fim depleted, IgG anti- 
Fim depleted, IgA anti-Fim depleted). Data represent mean ± SD of five 
independent experiments, performed with PMN isolated from different 
donors.
Log Green-Fluorescence Intensity (AU)
lacking detectable antibody titers against pertussis, exhibited 
no influence on bacterial adherence levels, confirming the 
importance of specific antibodies on attachment inhibition.
The analysis of 24 sera samples taken after pertussis vaccina­
tion showed that Fim-specific antibodies play a major role in 
such inhibition. We further found both IgA and IgG isotypes 
to be responsible for reducing B. pertussis attachment. In the 
case of serum, this activity proved to be primarily dependent 
on the level of Fim antibodies present in those fractions. 
However, previous studies performed with A549 or other 
cell lines (Reiman et al., 1989; van den Akker, 1998; Alonso 
etal., 2001; Coutte etal., 2003) had shown FHAbut not Fim 
to be the main adhesin of B. pertussis. Accordingly, we 
observed that the lack of expression of FHA determined a 
drastic decrease on bacterial attachment to A549 cells, 
whereas the attachment efficiency of both wild type B. 
pertussis and B. pertussis mutant lacking expression of 
fimbriae were equivalent. FHA directed antibodies, however, 
were shown to have a moderate effect on B. pertussis 
attachment compared to the decrease observed in the 
presence of Fim-directed antibodies. These results indicate 
that B. pertussis fimbriae are not critical for bacterial 
attachment, but rather constitute a target for efficient anti­
body-mediated prevention of bacteria-epithelial cell inter­
action. Consistent with this hypothesis, the presence of sera 
capable of blocking wild-type B. pertussis attachment did 
not modify Fim-deficient isogenic strain adherence. Anti­
body-mediated bacterial agglutination seems to underlie 
this phenomenon. Fim-directed antibodies and antibodies 
aganist Prn and LPS had been previously described as 
agglutinins (Li et al., 1988a,b; Brennan et al., 1988). How­
ever, as found by others (Mink et al., 1994), our results 
showed anti-Fim antibodies to be the main agglutinin 
present in both postvaccination and postinfection human 
sera. Human sera containing anti-Fim antibodies, but not 
sera depleted of anti-Fim antibodies, induced wild-type 
bacteria agglutination. Additionally, human sera capable of 
agglutinating wild-type B. pertussis strain failed to aggluti­
nate Fim-deficient isogenic strain at the same concentra­
tions. Microscopic analysis further confirmed that only 
under agglutinating conditions is there a drastic reduction 
in the number of bacteria attached to the respiratory cell.
These results support the hypothesis that the ability of 
anti-Fim antibodies to reduce bacterial attachment might 
primarily be related to the induction of bacterial agglutina­
tion. The strong correlation between the decrease in bacter­
ial attachment levels and both the sera agglutinating activity 
and the Fim antibody level is consistent with this hypothesis. 
Previous results reported by van den Berg et al. (1999) 
suggested that antibodies directed against any surface struc­
ture of B. pertussis would interfere with bacterial adherence 
to bronchial epithelial cells. Having performed the studies 
using nonagglutinating concentrations of each antibody 
tested, as reported in their article, the moderate effect of 
anti-Fim antibodies on B. pertussis attachment seems to be 
consistent with our findings.
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Sera agglutinating activity have been found correlated 
with protection in early vaccine trials (Medical Research 
Council, 1956). The presence of this activity in human sera 
was later attributed mainly to Fim antibodies (Mink et al., 
1994), but the mechanism by which agglutinins provide 
protection was not elucidated. Bacterial aggregation, pre­
viously found to be detrimental for colonization (Coutte 
etal., 2003), may preclude efficient bacteria-cell interaction, 
but may also facilitate bacterial clearance by immune cells. 
In this study we found bacterial agglutination not to 
influence B. pertussis phagocytosis significantly, but rather 
to interfere with bacterial attachment to host cells. The data 
stress the importance of multivalency of vaccines. Such 
vaccines are not only capable of inducing high titers, but 
may also facilitate the induction of multiple and synergistic 
lines of host defense.
In summary, our data suggest that anti-Fim antibodies 
induced by either vaccination or infection to promote a 
specific mechanism of host defense by interfering Bordetel­
la—respiratory cell interaction. These results provide a bio­
logical basis for the field trial investigation, reporting 
increased protection against B. pertussis by vaccines includ­
ing Fim, and the reported association of high antibody titers 
against Fim with a lower likelihood of acquiring pertussis 
(Cherry etal., 1998; Storsaeter etal., 1998).
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